Ken Griffin Roivant Sciences Ltd. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Citadel Advisors LLC holds 69,400 shares of ROIV stock, worth $836,270. This represents 0.0% of its overall portfolio holdings.
Number of Shares
69,400
Previous 97,200
28.6%
Holding current value
$836,270
Previous $1.02 Million
28.42%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ROIV
# of Institutions
308Shares Held
496MCall Options Held
989KPut Options Held
1.15M-
Sb Investment Advisers (Uk) LTD London, X071.4MShares$860 Million6.97% of portfolio
-
Viking Global Investors LP69.2MShares$833 Million2.91% of portfolio
-
Qvt Financial LP New York, NY66.7MShares$804 Million72.99% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$426 Million0.01% of portfolio
-
Morgan Stanley New York, NY29.3MShares$353 Million0.02% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.49B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...